Return to homepagePandemic Pact

Use of drugs that increase the expression of ACE2 and risk of COVID-19: A case-population study.

  • Funded by National Institute of Health Carlos III [El Instituto de Salud Carlos III] (ISCIII)
  • Total publications:0 publications

Grant number: COV20_00027

Grant search

Key facts

  • Disease

    COVID-19

  • Start & end year

    N/A

  • Funder

    National Institute of Health Carlos III [El Instituto de Salud Carlos III] (ISCIII)

  • Principal Investigator

    Francisco José de Abajo Iglesias

  • Research Location

    Spain

  • Lead Research Institution

    FUNDACION INVESTIGACION BIOMEDICA HOSP. PRINCIPE DE ASTURIAS

  • Research Priority Alignment

    N/A

  • Research Category

    Epidemiological studies

  • Research Subcategory

    Disease susceptibility

  • Special Interest Tags

    N/A

  • Study Type

    Clinical

  • Clinical Trial Details

    Not applicable

  • Broad Policy Alignment

    Pending

  • Age Group

    Unspecified

  • Vulnerable Population

    Unspecified

  • Occupations of Interest

    Unspecified

Abstract

SARS-CoV-2 uses angiotensin converting enzyme 2 (ACE2) to penetrate cells and replicate. It is known that certain drugs increase the expression of ACE2 and could facilitate the entry of the virus and increase the severity of the infection. It is intended to carry out an epidemiological study of cases and controls, taking as cases the patients hospitalized for COVID-19 in the participating hospitals (subclassified by severity) and primary care population controls extracted from the BIFAP database and matched with the cases by age. (exact), sex and index date. Information on prescribed drugs and comorbidities will be extracted from hospital and Bofap medical records, and the adjusted Odds Ratio will be computed using conditioned logistic regression models. The extraction of information from mild COVID-19 + cases not hospitalized as an alternative series of controls (ratio 1: 1) will be considered.